Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Rebecca L Shattuck-BrandtSheau-Chiann ChenEmily MurrayChristopher Andrew JohnsonHolly CrandallJamye F O'NealRami Nayef Al-RohilCaroline A NebhanVijaya BhartiKimberly B DahlmanGregory D AyersChi YanMark C KelleyRondi M KauffmannMary HooksAna GrauDouglas B JohnsonAnna E VilgelmAnn RichmondPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
KRT-232 is an effective therapy for the treatment of either BRAFWT or PAN WT (BRAFWT, NRASWT) TP53WT melanomas. In combination with BRAF and/or MEK inhibitors, KRT-232 may be an effective treatment strategy for BRAFV600-mutant tumors.
Keyphrases